#None #Webinar #radiopharmaceuticals #Xtalks

Accelerating Radiopharmaceutical Therapy with Translational Tools: A Must-Attend Webinar

Join us for a comprehensive and informative webinar hosted by Xtalks, where participants will delve into the crucial choice of selecting and validating preclinical tumor models. The focus will be on capturing relevant target biology and implementing effective translational endpoints that can lead to successful treatment outcomes.

Radioligand therapy has shown remarkable progress, yet various stages of development can stall. This often occurs due to a lack of appropriate preclinical models, inadequate study designs, or improper isotopic selection. Thus, understanding the interplay amongst these aspects is vital for informed decision-making that minimizes risks in development and validates therapeutic targets for clinical translation.

Key Highlights of the Webinar

1. Selection of Preclinical Tumor Models:
Attendees will learn how to choose appropriate tumor models that provide insights into the relevant biology and target expression. Understanding these models is essential for bridging the gap from preclinical studies to clinical applications.

2. Radiochemistry Considerations:
The webinar will feature discussions on radiochemistry, particularly isotope labeling strategies and how they ensure reliable data generation. Such knowledge is crucial for making effective decisions based on solid scientific foundations.

3. Designing Efficient Studies:
Best practices for designing biodistribution, dosimetry, and efficacy studies will be presented. These studies are key for generating actionable data that significantly enhances clinical decisions.

4. Case Study Examination:
A case study on glioblastoma leveraging the [¹⁷⁷Lu]FAP-2886 in the U87MG model will illustrate how to validate targets and evaluate efficacy. This real-world example underscores the importance of robust study designs and imaging techniques in assessing therapeutic potential.

Expert Speakers

The webinar will feature prominent industry-leading experts, including Mike Batey, Senior Director of SMS Discovery, and Julian Goggi, PhD, Director of Discovery Research. They bring extensive knowledge and insight into the radioligand therapy domain.

Date and Registration Details

Mark your calendar for this event scheduled for November 14, 2025, at 9 am EST (3 pm CET). This is a prime opportunity for researchers, drug developers, and translational scientists focused on advancing radioligand therapies to interact with experts and refine their understanding of the subject matter.

Don't miss the chance to learn about imaging-based metrics that can transform radiopharmaceutical therapy, minimize developmental risks, and push promising treatments closer to patient access.
For more information and to secure your spot for this invaluable session, visit Xtalks official webinar page. There is no fee for registration!

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., stands as a premier provider of educational content and webinars throughout the life science, healthcare, and medical device sectors. Each year, industry professionals from pharmaceutical companies to academic institutions count on Xtalks for timely updates on developments, regulations, and innovations within the field. With a commitment to delivering quality content and insights from industry leaders, Xtalks contributes to shaping informed professionals adept at navigating their fields.